Latest Biochemistry of Alzheimer's disease Stories
A highly toxic beta-amyloid – a protein that exists in the brains of Alzheimer's disease victims – has been found to greatly increase the toxicity of other more common and less toxic beta-amyloids, serving as a possible "trigger" for the advent and development of Alzheimer's, researchers at the University of Virginia and German biotech company Probiodrug have discovered.
UC Davis researchers have found novel compounds that disrupt the formation of amyloid, the clumps of protein in the brains of people with Alzheimer's disease believed to be important in causing the disease's characteristic mental decline.
Studying a mouse model of Alzheimer's disease, neuroscientists at the Technische Universitaet Muenchen have observed correlations between increases in both soluble and plaque-forming beta-amyloid – a protein implicated in the disease process – and dysfunctional developments on several levels: individual cortical neurons, neuronal circuits, sensory cognition, and behavior.
Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65.
Alzheimer’s disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65.
The deposition of amyloid beta in the brain of individuals with Alzheimer's disease is the focus of much research into both its cause and treatment.
Alzheimer's disease is the sixth leading cause of death in the United States and the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression.
A meta-analysis of previously published studies found that the ratio of blood plasma amyloid-β (Aβ) peptides Aβ42:Aβ40 was significantly associated with development of Alzheimer disease and dementia.
An international team of researchers have developed a new method for measurement of aggregated beta-amyloid – a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer's disease.
Antibodies that block the process of synapse disintegration in Alzheimer's disease have been identified, raising hopes for a treatment to combat early cognitive decline in the disease.
- The act of sweetening by admixture of some saccharine substance.